Market Overview

Citigroup Reiterates Buy Rating, $31 PT on Ariad Pharmaceuticals

Related ARIA
Ariad Pharmaceuticals Responds To Congressional Letter
Watch These 4 Huge Put Purchases In Friday Trade

In a report published Friday, Citigroup reiterated its Buy rating and $31.00 price target on Ariad Pharmaceuticals (NASDAQ: ARIA).

Citigroup noted, “Today's announcement of the over 3 month early decision for the approval of Iclusig (ponatinib) in CML is a positive surprise, but the inclusion of a black box warning on the label was not in consensus expectation, in our view. We note that Tasigna has a black box warning and Sprycel, while no black box warning, has many warnings including pleural infusions (accumulation of fluid around the lungs).”

Ariad Pharmaceuticals closed on Thursday at $23.88.

Latest Ratings for ARIA

Oct 2016SunTrust Robinson HumphreyInitiates Coverage onBuy
Sep 2016Leerink SwannInitiates Coverage onOutperform
Jul 2016BarclaysMaintainsUnderweight

View More Analyst Ratings for ARIA
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Reiteration Analyst Ratings


Related Articles (ARIA)

View Comments and Join the Discussion!